Previous Article | Next Article 
Journal of Virology, July 1999, p. 5431-5437, Vol. 73, No. 7
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Identification of a Cytoplasmic Targeting/Retention
Signal in a Retroviral Gag Polyprotein
Gyu
Choi,1
Sunyoung
Park,1
Bongkun
Choi,1
Suntaek
Hong,1
Jiyeon
Lee,1
Eric
Hunter,2 and
Sung S.
Rhee1,*
Laboratory of Molecular Virology, Samsung
Biomedical Research Institute, Seoul, Korea,1
and Department of Microbiology, University of Alabama at
Birmingham, Birmingham, Alabama 352942
Received 19 January 1999/Accepted 24 March 1999
 |
ABSTRACT |
Retroviral capsid assembly can occur by either of two distinct
morphogenic processes: in type C viruses, the capsid assembles and buds
at the plasma membrane, while in type B and D viruses, the capsid
assembles within the cytoplasm and is then transported to the plasma
membrane for budding. We have previously reported that a
single-amino-acid substitution of a tryptophan for an arginine in the
matrix protein (MA) of Mason-Pfizer monkey virus (MPMV) converts its
capsid assembly from that of a type D retrovirus to that of the type C
viruses (S. S. Rhee and E. Hunter, Cell 63:77-86, 1990). Here we
identify a region of 18 amino acids within the MA of MPMV that is
responsible for type D-specific morphogenesis. Insertion of these 18 amino acids into the MA of type C Moloney murine leukemia virus causes
it to assemble an immature capsid in the cytoplasm. Furthermore, fusion
of the MPMV MA to the green fluorescent protein resulted in altered
intracellular targeting and a punctate accumulation of the fusion
protein in the cytoplasm. These 18 amino acids, which are necessary and
sufficient to target retroviral Gag polyproteins to defined sites in
the cytoplasm, appear to define a novel mammalian cytoplasmic
targeting/retention signal.
 |
INTRODUCTION |
Electron microscopic (EM) studies
have revealed two morphologically distinct pathways for capsid assembly
in different retroviruses. In type C morphogenic viruses, such as
murine leukemia virus (MuLV) and human immunodeficiency virus, Gag
polyproteins are synthesized in the cytoplasm and then transported to
the plasma membrane, where they are assembled into an icosahedral
capsid. In contrast, the Gag polyproteins of type B and D viruses, such
as mouse mammary tumor virus (MMTV) and Mason-Pfizer monkey virus
(MPMV), are assembled into a capsid within the cytoplasm prior to
transport to the cell membrane. Therefore, the newly synthesized Gag
polyprotein appears to contain the necessary signals to direct its
transport to or retention at the site of capsid self-assembly.
Our previous studies of MPMV demonstrated that a single-amino-acid
substitution (mutant R55W) in the matrix protein (MA) could alter the
capsid assembly site of type D viruses from a region within the
cytoplasm to the inner surface of the plasma membrane (32).
Others have reported that human immunodeficiency virus and Moloney
murine leukemia virus (MoMuLV) with amino acid substitutions or
deletions in MA undergo capsid assembly within cytoplasmic vacuoles
rather than at the plasma membrane (3, 10, 12, 38). These
studies strongly suggest that MA can play an essential role in
determining the intracellular transport of Gag polyproteins to the site
of capsid assembly. Moreover, they suggest that there are no inherent
differences in the process of capsid assembly for different
retroviruses; they differ only in the intracellular site to which Gag
polyproteins are targeted and accumulated for assembly.
Based on mutagenic studies of MPMV MA, we proposed a model for
intracytoplasmic assembly of type D retrovirus capsids
(30-32). In MPMV-infected cells, Gag polyproteins,
synthesized and modified with myristic acid in the cytosol, are
transported to a defined site within the cytoplasm. There, the
molecules presumably reach a sufficiently high concentration for
efficient assembly of an immature capsid. The assembled capsids then
become transport competent and are rapidly transported to the plasma
membrane by an energy-dependent (40) intracytoplasmic
transport machinery of the cell. Previous studies provide evidence for
a cytoplasmic targeting/retention signal (CTRS) in MA that is
responsible for intracytoplasmic capsid assembly in Type D
retroviruses. This putative CTRS appears to act dominantly to retain
Gag molecules at a site of intracytoplasmic capsid assembly. Without
this CTRS, they would be individually transferred to a site at the
plasma membrane where they would self-assemble concurrently with virus
budding, as observed with MPMV mutant R55W (32) and,
presumably, with type C viruses.
Interestingly, a region of 18 amino acids spanning residues 43 to 60 within MPMV MA is highly conserved between MPMV and MMTV (32). This region includes the arginine residue at position 55, which when mutated, can alter the capsid assembly site.
Furthermore, recent nuclear magnetic resonance studies show that these
18 residues form an exposed loop on the surface of the MA protein
(5). By contrast, this amino acid stretch appears to be
partly deleted in MoMuLV MA: residues equivalent to 50 to 55 of MPMV MA
are missing in MoMuLV MA, while flanking residues are highly conserved.
Thus, we postulated that this short stretch of amino acids might
function as a CTRS for type B- and D-specific intracytoplasmic capsid assembly.
In the present study, we have tested this hypothesis by determining
whether this 18-amino-acid putative MPMV CTRS sequence can alter the
site of MoMuLV capsid assembly. A mutant of MoMuLV, MLV/D-CTRS, was
generated to contain the putative CTRS sequence of 18 amino acids from
MPMV (D-CTRS) in the place of the 11 amino acids at the equivalent
position in MoMuLV MA. Cells transfected with this mutant genome
assemble immature capsids in the cytoplasm and not at the cellular
membrane. Thus, these 18 amino acids are sufficient to direct proteins
to the cytoplasm. Furthermore, MPMV MA tagged with the green
fluorescent protein (GFP) accumulates at discrete spots in the
cytoplasm. In contrast, mutant MA-GFP with the arginine substitution
was found associated with the plasma membrane.
 |
MATERIALS AND METHODS |
DNAs and cells.
To generate mutants of MoMuLV,
oligonucleotide-directed mutagenesis was carried out with various
synthetic oligonucleotides as previously described (43). A
1.7-kbp SstI-XhoI fragment containing the entire
coding sequence of MA from an infectious MoMuLV proviral DNA, pMOV3
(kindly provided by R. V. Srinivas, University of Alabama at
Birmingham), was subcloned into vector M13mp18 to perform the mutagenesis. After mutagenesis, the mutated fragments were recloned into the MoMuLV expression vector pHMLV to replace the wild-type fragment, and the presence of the mutations was confirmed by dideoxy sequencing of the double-stranded DNA (36). The plasmid,
pHMLV, contains an infectious MoMuLV proviral genome derived from pMOV3 and a hygromycin resistance gene under the control of the simian virus
40 early promoter.
To determine the subcellular localization of the putative
CTRS-containing MA protein, the coding region of MPMV MA was amplified by PCR and then fused in frame to the N terminus of enhanced GFP from
the jellyfish Aequorea victoria (pEGFP; Clonetech) to
generate plasmid pMAD-CTRS/GFP. Plasmid
pMAC-CTRS/GFP is a derivative of MPMV mutant R55W.
To establish cell lines containing integrated wild-type or mutant
proviral DNA, semiconfluent monolayers of murine BALB/c 3T3 fibroblast
SV-T2 cells (ATCC CCL-163.1) that are negative for MuLV were
transfected with viral DNAs linearized with FspI as
described previously (33). Cell colonies were selected in medium containing 400 mg of hygromycin B (GIBCO BRL)/ml and screened to
determine whether they expressed viral structural proteins.
For the transient expression of viral proteins in COS-1 cells, the
cells were transfected with either wild-type pHMLV or mutant DNA (3 mg/35-mm-diameter plate) by the modified calcium phosphate precipitation method as described by Chen and Okayama (4).
Radiolabeling and immunoprecipitation of virus proteins.
Cells were pulse-labeled for 20 to 30 min with
[3H]leucine (0.8 mCi/ml; 157 Ci/mmol; DuPont) and chased
for 4 h in complete growth medium as previously described
(31). For fatty acid labeling, the cells were labeled with
[9,10-3H]myristic acid (0.5 mCi/ml; DuPont) for 2 h
(31).
Following lysis in lysis buffer A (1% Triton X-100, 1% sodium
deoxycholate, 0.15 M NaCl, 0.05 M Tris [pH 7.5]), cell-associated viral proteins were immunoprecipitated with goat anti-MuLV antiserum (Division of Cancer Cause and Prevention, National Cancer Institute) or
rabbit anti-Gag antibodies (31). Radiolabeled virus
particles that were released into the culture medium were pelleted by
centrifugation for 10 min at 80,000 rpm in a Beckman TLA 100 rotor at
4°C and lysed in lysis buffer B (0.1% sodium dodecyl sulfate
[SDS], 1% Triton X-100, 1% sodium deoxycholate, 0.15 M NaCl, 0.05 M
Tris [pH 7.5]). Virion-associated viral proteins were then
immunoprecipitated with goat anti-MuLV antiserum.
The immunoprecipitated viral proteins were separated with a 12%
resolving gel by SDS-polyacrylamide gel electrophoresis.
Fractionation of Gag polyprotein, capsid preparation, and Western
blot analyses.
Gag polyproteins were fractionated into free and
capsid-associated forms as previously described (32) with
some modifications. Briefly, approximately 5 million SV-T2 cells of
wild-type and mutant lines were lysed at room temperature for 1 h
in 1 ml of ICAP buffer (1% Triton X-100, 0.25 M sucrose, 1.0 mM EDTA,
10 mM Tris [pH 7.5], 10 mg of DNase I/ml, 1 mg of leupeptin/ml, 1 mg
of aprotinin/ml, 100 mg of phenylmethylsulfonyl fluoride/ml) supplemented with 500 mM NaCl to disrupt the Gag polyprotein
association with cytoskeletal elements (8, 9). After removal
of nuclei from the lysates by centrifugation for 5 min in a
microcentrifuge at 4°C, the capsids were pelleted through a 35%
sucrose cushion by centrifugation at 80,000 rpm for 15 min in a Beckman
TLA120.2 rotor at 4°C. Viral proteins in each fraction were
separately immunoprecipitated with rabbit anti-Gag antiserum, separated
by SDS-polyacrylamide gel electrophoresis and visualized by
immunoblotting with rabbit anti-Gag antibodies and
peroxidase-conjugated donkey anti-rabbit antibodies with an enhanced
chemiluminescence detection system (ECL; Amersham).
The sedimentable particles in the pellet fraction were further purified
through a continuous 30 to 50% (wt/wt) linear sucrose gradient. The
pellet fraction, obtained from approximately 60 million cells of the
MLV/D-CTRS line as described above, was resuspended in 0.6 ml of ICAP
buffer on ice for 2 h and then layered onto a 10-ml sucrose
gradient. After centrifugation for 3 h at 36,000 rpm in a Beckman
SW41 rotor at 20°C, fractions of 1 ml each were collected from the
bottom, diluted with 1 ml of phosphate-buffered saline (PBS), and then
ultracentrifuged at 80,000 rpm for 15 min in a Beckman TLA120.2 rotor
at 4°C. The resulting pellets were analyzed to detect Gag
polyproteins by Western blot assay with goat anti-MuLV antibodies
followed by alkaline phosphatase-conjugated rabbit anti-goat antibodies.
Microscopic analyses.
For EM studies of capsid assembly,
COS-1 cells were transfected with virus DNA, fixed for 1 h at room
temperature with 1% glutaraldehyde, and washed in PBS. After
postfixation with 1% osmium tetroxide, the cells were embedded in an
epoxy resin mixture, sectioned, and stained with uranyl acetate and
lead nitrate. All preparations were examined with a Philips 301 EM.
The in vivo subcellular localization of the fluorescence-tagged MA
proteins was determined on a Bio-Rad MRC 1024 confocal microscope
system with LaserSharp software. COS cells, transfected with pEGFP,
pMAD-CTRS/GFP, or pMAC-CTRS/GFP and grown on
glass coverslips, were washed with PBS and fixed with 4%
paraformaldehyde in PBS for 20 min at room temperature. For GFP
excitation, an argon laser at 488-nm wavelength was used.
 |
RESULTS |
Synthesis and processing of viral proteins in mutant
virus-expressing cells.
We generated four mutants of Mo-MuLV (Fig.
1). In MLV/D-CTRS, the putative CTRS
sequence of 18 amino acids from MPMV (D-CTRS) substitutes for the 11 amino acids (residues 44 to 54) at the equivalent position in MoMuLV
MA. MLV/C-CTRS contains the mutant CTRS, with tryptophan in place of
arginine at position 55, derived from mutant R55W (C-CTRS). MLV/B-CTRS
and MLV/MS have 18-amino-acid substitutions derived from the
homologous, putative type B-specific CTRS sequence of MMTV
(32) and from a multiple-alanine-substituted sequence,
respectively. The alanines in MLV/MA substitute for each of the
residues that are homologous between MPMV and MMTV.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of mutants of MoMuLV. The
arrangement of the structural proteins within the
gag-encoded polyprotein is schematically presented, with the
partial amino acid sequences of MoMuLV p15 (MA) protein. In MLV/D-CTRS
and MLV/C-CTRS, the 11 amino acids (residues 44 to 54) in MA, indicated
in the box, are replaced with the 18 amino acids of the putative CTRS
sequence of M-PMV (residues 43 to 60) and by the corresponding sequence
from mutant MPMV R55W, respectively. The R55W substitution is marked
with an asterisk. MLV/B-CTRS and MLV/MS have 18-amino-acid
substitutions derived from the homologous, putative type B-specific
CTRS sequence of MMTV (residues 44 to 61) and from a
multiple-alanine-substituted sequence, respectively.
|
|
COS-1 cells were transiently transfected with wild-type DNA or
MLV/D-CTRS or MLV/C-CTRS mutant DNA. Forty-eight hours after transfection, the cells were pulse labeled with
[3H]leucine for 20 min and chased for 4 h in
complete growth medium. Both cell-associated and
released-virion-associated proteins were analyzed by
immunoprecipitation with goat anti-MuLV antiserum (Fig.
2).

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 2.
Immunoprecipitation of cell- and virion-associated viral
proteins. To determine biosynthesis, processing, and release of viral
proteins, proviral-DNA-transfected or mock-transfected COS cells were
pulse labeled for 20 min with [3H]leucine (lanes 1 to 4)
and chased for 4 h (lanes 5 to 8). Virus-specific proteins were
immunoprecipitated from the lysed cells (cell-associated; lanes 1 to 8)
or from the medium (virion-associated; lanes 9 to 12) with goat
anti-MuLV antiserum.
|
|
Similar levels of two major precursor polyproteins, the Gag polyprotein
Pr65gag and the envelope (Env) precursor
gPr80env, were synthesized during the pulse
labeling by cells expressing mutant as well as wild-type genomes (Fig.
2, lanes 1 to 4). The mutant Gag polyproteins are slightly larger by an
amount consistent with the 7-amino-acid addition (18-amino-acid
substitution for 11 amino acids [Fig. 2, lanes 3 and 4]).
During virus maturation, the MoMuLV Gag polyprotein is processed by the
virus-encoded protease into four structural proteins: p15, pp12, p30,
and p10 (1, 39). The Env precursor is cleaved by a cellular
protease in the late Golgi compartment into two cell-associated
glycoproteins, gp70 and p15E (11, 19). Following virus
release, the transmembrane glycoprotein p15E is further processed by
the viral protease into the virion-associated p12E (19, 29).
As expected, the processing of Gag and Env precursors was clearly seen
after a 4-h chase in wild-type MoMuLV-expressing cells (Fig. 2, lane
6); the intensities of the two precursor protein bands
(gPr80env and Pr65gag)
decreased with a concomitant appearance of gp70, p30, and p15E. In
addition, extracellular virions that were released from the pulse-labeled cells during the 4-h chase could be detected from the
culture fluids, as observed with bands of p12E along with mature viral
proteins (Fig. 2, lane 10).
In cells expressing either mutant virus, normal processing of Env
precursors was observed with bands of gp70 and p15E (Fig. 2, lanes 7 and 8). However, no p30 band could be detected, even though a
significant proportion of the radiolabeled mutant Gag polyproteins was
lost during the chase period. Furthermore, no viral proteins were
detected in the culture medium (Fig. 2, lanes 11 and 12). Thus, both
mutant Gag polyproteins with the putative D- and C-CTRS sequences were
efficiently synthesized but were turned over (with an approximate 2-h
half-life) without being efficiently processed or released into the
culture medium.
Intracytoplasmic capsid assembly of the putative type D-specific
CTRS-containing Gag polyproteins.
In MPMV-infected cells,
completely assembled, intracytoplasmic immature capsids are stable and
pelletable under mild nonionic detergent conditions, while mature
capsids of virion particles as well as unassembled capsid precursors
(either at the plasma membrane or within the cytoplasm) are solubilized
(30, 32, 33). Exploiting these different sensitivities of
the capsids, we carried out similar experiments to determine whether
the mutant Gag polyproteins are preassembled into an immature capsid
within the cytoplasm, as observed with MPMV. Since Gag polyproteins
have been observed to form pelletable aggregates when they were
overexpressed in COS cells, we established SVT2 cell lines with
low-level expression of integrated wild-type or mutant proviral genomes.
Intracellular preassembled capsids were prepared as previously
described (32). After lysis of SV-T2 cells in ICAP buffer supplemented with 500 mM NaCl to disrupt the Gag polyprotein
association with cytoskeletal elements (8, 9), the capsids
were pelleted through a 35% sucrose cushion. Soluble Gag polyproteins
remained in the supernatant fraction while capsid-associated
polyproteins were recovered in the pellet fraction. Viral proteins in
each fraction were analyzed by immunoprecipitation and immunoblotting with rabbit anti-Gag antiserum (Fig. 3A).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 3.
Determination of intracytoplasmic capsid formation and
myristylation of mutant Gag polyproteins. (A) Western blot showing
intracytoplasmic immature capsid assembly in mock-infected cells (lanes
1 and 2) and in SV-T2 cells expressing wild-type MoMuLV (lanes 3 and
4), MLV/D-CTRS (lanes 5 and 6), and MLV/C-CTRS (lanes 7 and 8). The
cells were lysed in 1% Triton X-100-containing ICAP buffer and then
fractionated into soluble (S; lanes 1, 3, 5, and 7) and pelletable (P;
lanes 2, 4, 6, and 8) fractions by centrifugation. Gag polyproteins
(Pr65gag) in each fraction were
immunoprecipitated with rabbit anti-Gag antiserum and then visualized
by Western blot analysis. Ig, heavy chains of rabbit immunoglobulin
molecules. (B) The Gag polyprotein complexes in the pellet fraction of
MLV/D-CTRS cells were purified through a continuous 30 to 50% (wt/wt)
linear sucrose gradient. The fractions were collected from bottom to
top, diluted with PBS, and ultracentrifuged to pellet
high-molecular-weight particles. Particle-associated Gag polyproteins
were detected by Western blot assay. The density of fraction 5 is 1.20 g/ml. (C) Myristylation of mutant Gag polyproteins was determined by
labeling cells with [3H]leucine (lanes 1 to 4) or
[3H]myristic acid (lanes 5 to 8). Radiolabeled Gag
molecules of wild-type MoMuLV (lanes 2 and 6), MLV/D-CTRS (lanes 3 and
7), and MLV/C-CTRS (lanes 4 and 8), as well as mock-infected cells
(lanes 1 and 5), were immunoprecipitated with rabbit anti-Gag
antibodies.
|
|
Cell-associated Gag polyproteins (Pr65gag) of
wild-type MoMuLV were found only in the soluble fraction (Fig. 3A,
lane 3); none could be recovered from the pellet fraction (lane 4).
This result is consistent with our earlier observations that the
assembling capsid at the plasma membrane of type C morphogenic viruses
is a relatively fragile structure. Thus, it is easily disrupted under these conditions (32).
In cells expressing MLV/D-CTRS, mutant Gag molecules were recovered in
both fractions; approximately 20 to 30% of the total Gag molecules
appeared to have been incorporated into stable, pelletable particles
within the cytoplasm (Fig. 3A, lanes 5 and 6). Interestingly, no
detergent-resistant particles were obtained with MLV/C-CTRS (Fig. 3A,
lanes 7 and 8) that contains a mutated, presumably nonfunctional CTRS.
These detergent-resistant pelletable complexes obtained from
MLV/D-CTRS-expressing cells appear to be different from the large oligomeric structures of Gag polyproteins observed in human
immunodeficiency virus type 1-infected cells. The former were pelleted
through a 35% sucrose cushion, equivalent to a density of 1.14 to 1.15 g/ml, while the latter have a density of 1.10 to 1.13 g/ml
(21). Nevertheless, to confirm that these complexes resulted
from highly ordered structures of Gag polyproteins with the type
D-specific CTRS sequence, not from abnormal aggregates, pelletable
material in MLV/D-CTRS cell lysates was further purified through a
continuous 30 to 50% (wt/wt) linear sucrose gradient.
Most of the nonionic-detergent-resistant intracellular complexes of
MLV/D-CTRS Gag polyproteins sedimented in fraction 5 of the gradient
with a density of 1.20 g/ml (Fig. 3B), similar to that of naked
immature retroviral capsids (20, 23, 35). Thus, these
results, together with those mentioned above (Fig. 3A), strengthen the
possibility that the type D-specific CTRS sequence causes Gag
polyproteins to be retained within the cytoplasm for assembly of an
immature capsid.
This dramatic change appears to result from the CTRS addition alone,
not from a defect in myristylation of the proteins, in contrast to that
observed with mutant simian immunodeficiency viruses, where
nonmyristylated Gag precursors can assemble capsids within the
cytoplasm of insect cells (6). Mutant Gag molecules of both
MLV/D-CTRS and MLV/C-CTRS appear to be myristylated as efficiently as
wild-type proteins (Fig. 3C) when the amounts of Gag polyproteins pulse
labeled with [3H]leucine for 30 min (Fig. 3C, lanes 1 to
4) are compared to the amounts of those labeled with
[9,10-3H]myristic acid for 2 h (lanes 5 to 8).
EM analyses.
The data described above strongly indicate that
an insertion of 18 type D-specific amino acids into type C Gag
polyproteins altered the viral morphogenesis to preassemble an immature
capsid within the cytoplasm. However, these biochemical approaches
could not distinguish between intracytoplasmic capsids that had
assembled at a cytosolic site, as in type B and D viruses, and
intracisternal capsids that had been released into cytoplasmic
vacuoles, as in mutant type C viruses (3, 10, 12, 38). Thus,
the effects of these amino acids on capsid assembly were more
specifically evaluated by EM studies of COS cells transfected with
wild-type or mutant proviral DNAs.
MoMuLV-infected cells show capsids assembling and budding at the plasma
membrane, with numerous extracellular virions adjacent to the cells
(Fig. 4A). Unlike MuLV-expressing NIH3T3
cells, in which it has been reported that capsids assemble at
membranous intracellular sites (16), we have never observed
infected COS cells assembling wild-type MuLV capsid structures within
the cytoplasm. Thin-section electron micrographs of mutant
MLV/C-CTRS-expressing COS cells show plasma membrane-associated
structures at an early step in the assembly process (Fig. 4B). Thus,
substitution per se of 18 amino acids (residues 43 to 60, derived from
mutant MPMV R55W) for 11 amino acids (residues 44 to 54) in the MA
protein of MoMuLV does not interfere with Gag polyprotein transport to and association with the plasma membrane. It does, however, appear to
result in an assembly-release defect, since essentially no late budding
structures were observed and the previously described pulse-chase
experiments demonstrated a lack of virion release.

View larger version (106K):
[in this window]
[in a new window]
|
FIG. 4.
Electron micrographs of COS cells transfected with
wild-type and mutant proviral genomes. (A) Cells with wild-type MoMuLV
have assembling capsids at the plasma membrane (arrowhead) and release
extracellular virions (arrow) with typical type C morphogenesis. (B)
Cells with MLV/C-CTRS have plasma membrane-associated assembling capsid
structures but no released viruses. (C and D) Cells with MLV/D-CTRS
show capsids preassembled within the cytoplasm (C) and occasionally
show capsids in the process of budding at the plasma membrane (arrow in
panel D). Extracellular virions (arrowhead in panel D) can very rarely
be seen. (E and F) In cells with MLV/B-CTRS, preassembled capsids are
observed in the cytoplasm but not on the membrane (E) and a few capsids
are in the process of budding at the plasma membrane (F). (G) In cells
with MLV/MS, assembling capsids can be seen only at the plasma
membrane. Original magnifications: ×75,000 (A, B, E, F, and G) and
×102,000 (C and D).
|
|
In contrast, MLV/D-CTRS-expressing cells show no capsids assembling at
the plasma membrane (Fig. 4C). Instead, preassembled capsids are
observed deep in the cytoplasm, not associated with intracellular
membranes. Of note, we seldom detected intact capsids in the process of
budding at the plasma membrane, and even more rarely did we detect
extracellular virions (Fig. 4D).
The experiments described above demonstrate that a functional type
D-specific CTRS enables type C Gag polyproteins to be targeted and
retained at a cytoplasmic assembly site. Furthermore, we demonstrated that this morphogenic conversion is not simply the result of the conformational changes in Gag molecules caused by insertion of foreign
amino acids into the MA domain, since it was not observed with the
nonfunctional CTRS insertion. We further confirmed this conclusion by
EM studies of two additional mutants of MoMuLV, MLV/B-CTRS and MLV/MS
(Fig. 1). As with the mutant MLV/D-CTRS, MLV/B-CTRS viruses
preassemble immature capsids in the cytoplasm but not on the membrane
(Fig. 4E). A few capsids were also observed in the process of budding
at the plasma membrane, but without detectable levels of virions
released into the culture medium (Fig. 4F). By contrast, MLV/MS virus
shows assembling structures associated with the plasma membrane (Fig.
4G), similar to those of MLV/C-CTRS. These results exclude the
possibility that intracytoplasmic capsid assembly of D- or
B-CTRS-containing Gag polyproteins was induced by a signal-independent,
nonspecific process.
Intracellular localization of the putative CTRS-containing MA
protein fused to GFP.
We further evaluated the subcellular
localization of proteins containing the putative CTRS by using direct
fluorescence to avoid nonspecific artifacts introduced by staining
cells with antibodies in indirect immunofluorescence. Wild-type D-CTRS
and mutant C-CTRS in the context of MPMV MA were fused to the GFP from
the jellyfish A. victoria. GFP is widely used as a
fluorescence reporter in studies of protein localization because many
studies have shown that it does not alter protein trafficking. At
48 h after transfection, COS cells were imaged on a laser
fluorescent confocal microscope for a better resolution of cellular
structures (Fig. 5). The green staining
of GFP alone, as expected, is distributed throughout the cell, with
bright fluorescence at the nucleus (Fig. 5, panel GFP). Cells
expressing the D-CTRS-containing the MA-GFP fusion protein have
fluorescent deposits with irregular shapes distributed sporadically
within the cytoplasm (panel MAD-CTRS/GFP). These
fluorescent images are different from typical patterns of staining
associated with vesicles or other cellular structures, suggesting that
the fluorescence-tagged-MA protein with wild-type D-CTRS has
accumulated at specific cytoplasmic locations. By contrast, this
punctate cytoplasmic pattern was not observed with the MA-GFP chimera
with C-CTRS; the green staining is associated with the plasma membrane,
as well as with the nucleus (panel MAC-CTRS/GFP).

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 5.
Subcellular distribution of MA protein fused to GFP in
COS cells. The cells were transiently transfected with pEGFP,
pMAD-CTRS/GFP, or pMAC-CTRS/GFP, and the
fluorescence-tagged MA proteins were localized by laser fluorescent
confocal microscopy. The green staining of GFP alone is distributed
intensely in the nucleus and diffused faintly throughout the cytosol.
In cells with the putative D-CTRS-containing MA-GFP fusion proteins
(MAD-CTRS/GFP), fluorescent deposits can be seen
sporadically within the cytoplasm (arrows) with an irregular body
(inset). By contrast, GFP fused to mutant MA derived from mutant M-PMV
R55W (MAC-CTRS/GFP) displays fluorescent patches
associated with the plasma membrane (arrows) and a nuclear
distribution.
|
|
 |
DISCUSSION |
In cells, newly synthesized proteins are directed from their sites
of biosynthesis to their sites of activity by complex and highly
regulated processes. To date, studies of many proteins have revealed
the presence of signaling sequences within the primary structure
of proteins. These sequences play an indispensable role in directing
proteins to their destinations. The signals on secreted and
membrane-spanning proteins and on proteins that direct them to the
cellular organelles, such as nucleus, mitochondria, and chloroplasts,
have been identified (2, 7, 15, 17, 18, 34). However,
the intracytoplasmic trafficking by which proteins are targeted
to other active sites within the cytoplasm is less well understood,
even though it is likely that is also a highly directed and regulated process.
Previously, we proposed that the MA protein of MPMV, the prototype of
the type D retroviruses, contains a specific, dominant signal that is
essential to target Gag polyproteins to a site within the cytoplasm for
type D-specific intracytoplasmic capsid assembly (32). When
this signal was disrupted by a single-amino-acid substitution in MA
(mutant R55W), Gag molecules no longer accumulated at the usual
cytoplasmic sites. Instead, individual proteins were transported to the
inner surface of the plasma membrane, where they self-assembled
concurrently with virus budding, as observed with type C
retroviruses. In this report, we have identified 18 amino acids,
spanning residues 43 to 60 within MPMV MA, that act as a topogenic
CTRS. When these 18 amino acids were inserted into the MA of type C
MoMuLV, the capsid assembly process was altered to assemble an immature
capsid in the cytoplasm. Interestingly, nuclear magnetic resonance has
shown that these residues form a loop that is exposed on the surface of
the MPMV MA protein (5). Thus, our findings imply that these
18 amino acids, presumably exposed on the surface of the MuLV Gag
polyprotein, are sufficient to function as a CTRS to localize proteins
within the cytoplasm. Moreover, these results confirm our previous
results indicating that there are no inherent differences in the
process of capsid assembly for different retroviruses; they differ only
in the intracellular site to which Gag polyproteins are targeted and
accumulated for assembly.
The MA protein of type C retroviruses has been suggested to play a
critical role in transporting Gag polyproteins to the plasma membrane.
Specifically, the basic residues, as well as myristic acid modification
within the amino-terminal region of the protein, were found to form a
bipartite plasma membrane-targeting signal (14, 28, 38, 41,
42). In the present study, we found that this signal appears to
still be functional even with an amino acid insertion after the basic
patch of mutant MuLVs. When a multiply substituted sequence (MLV/MS) or
a nonfunctional CTRS (MLV/C-CTRS) was inserted, myristylated mutant Gag
proteins were targeted to the plasma membrane and assembled capsids
there (Fig. 3 and 4). This shows that the morphogenic conversion
observed in mutant MuLV with the wild-type CTRS (mutant MLV/D-CTRS and
MLV/B-CTRS) was not induced by the simple aggregation of Gag proteins
at the site of biosynthesis. It is probable that the functional
CTRS-containing Gag molecules accumulate at a defined site in the
cytoplasm by specific signal-directed intracytoplasmic protein
transport for capsid assembly. Consistent with our previous result with
mutant MPMV R55W, where mutant Gag was efficiently and rapidly
transported to the plasma membrane (32), these data suggest
that the plasma membrane-targeting information in retroviral Gag must
be overridden by the insertion of a dominant CTRS. This is supported by
the results demonstrating that the MPMV MA protein accumulated in punctate patches within the cytoplasm, whereas mutant MA with the
nonfunctional CTRS is found associated with the plasma membrane (Fig.
5). Furthermore, this pattern of distribution confirms our conclusion
that the sequence of 18 amino acids in the MA protein of MPMV is
critical to target and localize proteins to a specific site within the cytoplasm.
Although mutant Gag polyproteins were synthesized at a normal level and
directed to an appropriate site, our biochemical assays demonstrated no
detectable release of mutant virion particles (Fig. 2). In cells with
mutant MLV/C-CTRS and MLV/MS, we observed only plasma
membrane-associated structures at an early step in the assembly
process. Furthermore, no capsids were detected assembling at the late
stages. This implies that the insertion mutations described here do not
interfere with protein transport to and association with the plasma
membrane but do interfere with protein stability (causing the shorter
half-life [Fig. 2]) and with the capsid assembly process. These
effects could explain our finding of inefficient capsid assembly in the
functional CTRS-containing MoMuLV: only a small portion of the total
accumulated Gag molecules were associated with the nonionic
detergent-resistant capsid (Fig. 3A), and few intracellular capsids
were detected. It is also possible that efficient assembly of immature
capsids in the cytoplasm may require other domains that are present in
MPMV Gag polyproteins but missing in these MuLV chimeras. Indeed, MPMV
mutants with deletions in the p12 domain that is present in type B and
D viruses but absent from MuLV were severely impaired for capsid
assembly (37).
In summary, the data presented here suggest the existence of a novel
mechanism by which a cytoplasmic protein is specifically retained
within the cytoplasm. Furthermore, this intracytoplasmic trafficking of
proteins, as with proteins destined for the nucleus, mitochondria, and
other organelles (7, 15, 17, 18, 22), appears to be
specified by a short signal sequence within the primary structure of
the protein. Numerous cellular proteins have been suggested to be
receptor proteins that recognize signal sequences and mediate protein
transport (13, 24-27). It seems likely, then, that specific
eucaryotic CTRS receptor proteins direct and retain Gag polyproteins at
specific cytoplasmic locations by using the host cell transport
machinery. The discovery of this CTRS sequence may not only enhance our
understanding of viral transport and assembly but also help elucidate
the general process of intracytoplasmic protein trafficking in
eucaryotic cells.
 |
ACKNOWLEDGMENTS |
We thank E. Arms at UAB for excellent technical assistance in the
EM. We are grateful to members of our laboratory for discussions during the project and to J. Macke for substantive editing of the manuscript.
This work was supported by grant B-95003 to S.S.R. from the Samsung
Biomedical Research Institute and by a grant to E.H. from the National
Cancer Institute (R39 CA27834).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Molecular Virology, Samsung Biomedical Research Institute, Kangnam-Ku, Ilwon-Dong 50, Seoul 135-230, Korea. Phone: 82-2-3410-3632. Fax: 82-2-3410-3649. E-mail: ssrhee{at}smc.samsung.co.kr.
 |
REFERENCES |
| 1.
|
Arcement, L. J.,
W. I. Karshin,
R. B. Naso, and R. B. Arlinghaus.
1977.
"Gag" polyprotein precursors of Rauscher murine leukemia virus.
Virology
81:284-297[Medline].
|
| 2.
|
Blobel, G.
1980.
Intracellular protein topogenesis.
Proc. Natl. Acad. Sci. USA
77:1496-1500[Abstract/Free Full Text].
|
| 3.
|
Cannon, P. M.,
S. Matthews,
N. Clark,
E. D. Byles,
O. Iourin,
D. J. Hockley,
S. M. Kingsman, and A. J. Kingsman.
1997.
Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17.
J. Virol.
71:3474-3483[Abstract].
|
| 4.
|
Chen, C., and H. Okayama.
1987.
High-efficiency transformation of mammalian cells by plasmid DNA.
Mol. Cell. Biol.
7:2745-2752[Abstract/Free Full Text].
|
| 5.
|
Conte, M. R.,
M. Klikova,
E. Hunter,
T. Ruml, and S. Matthews.
1997.
The three-dimensional solution structure of the matrix protein from the type D retrovirus, the Mason-Pfizer monkey virus, and implications for the morphology of retroviral assembly.
EMBO J.
16:5819-5826[Medline].
|
| 6.
|
Delchambre, M.,
D. Gheysen,
D. Thines,
C. Thiriart,
E. Jacobs,
E. Verdin,
M. Horth,
A. Burny, and F. Bex.
1989.
The GAG precursor of simian immunodeficiency virus assembles into virus-like particles.
EMBO J.
8:2653-2660[Medline].
|
| 7.
|
Dingwall, C., and R. A. Laskey.
1991.
Nuclear targeting sequences a consensus?
Trends Biochem. Sci.
16:478-481[Medline].
|
| 8.
|
Edbauer, C. A., and R. B. Naso.
1984.
Cytoskeleton-associated Pr65gag and assembly of retrovirus temperature-sensitive mutants in chronically infected cells.
Virology
134:389-397[Medline].
|
| 9.
|
Edbauer, C. A., and R. B. Naso.
1983.
Cytoskeleton-associated Pr65gag and retrovirus assembly.
Virology
130:415-426[Medline].
|
| 10.
|
Facke, M.,
A. Janetzko,
R. L. Shoeman, and H. G. Krausslich.
1993.
A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum.
J. Virol.
67:4972-4980[Abstract/Free Full Text].
|
| 11.
|
Famulari, N. G.,
D. L. Buchhagen,
H. D. Klenk, and E. Fleissner.
1976.
Presence of murine leukemia virus envelope proteins gp70 and p15(E) in a common polyprotein of infected cells.
J. Virol.
20:501-508[Abstract/Free Full Text].
|
| 12.
|
Freed, E. O.,
J. M. Orenstein,
A. J. Buckler-White, and M. A. Martin.
1994.
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production.
J. Virol.
68:5311-5320[Abstract/Free Full Text].
|
| 13.
|
Gorlich, D.
1997.
Nuclear protein import.
Curr. Opin. Cell Biol.
9:412-419[Medline].
|
| 14.
|
Gottlinger, H. G.,
J. G. Sodroski, and W. A. Haseltine.
1989.
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
86:5781-5785[Abstract/Free Full Text].
|
| 15.
|
Gould, S. G.,
G. A. Keller, and S. Subramani.
1987.
Identification of a peroxisomal targeting signal at the carboxy terminus of firefly luciferase.
J. Cell Biol.
105:2923-2931[Abstract/Free Full Text].
|
| 16.
|
Hansen, M.,
L. Jelinek,
R. S. Jones,
J. Stegeman-Olsen, and E. Barklis.
1993.
Assembly and composition of intracellular particles formed by Moloney murine leukemia virus.
J. Virol.
67:5163-5174[Abstract/Free Full Text].
|
| 17.
|
Horwich, A.
1990.
Protein import into mitochondria and peroxisomes.
Curr. Opin. Cell Biol.
2:625-633[Medline].
|
| 18.
|
Kalderon, D.,
B. L. Roberts,
W. D. Richardson, and A. E. Smith.
1984.
A short amino acid sequence able to specify nuclear location.
Cell
39:499-509[Medline].
|
| 19.
|
Karshin, W. L.,
L. J. Arcement,
R. B. Naso, and R. B. Arlinghaus.
1977.
Common precursor for Rauscher leukemia virus gp69/71, p15(E) and p12(E).
J. Virol.
23:787-798[Abstract/Free Full Text].
|
| 20.
|
Klikova, M.,
S. S. Rhee,
E. Hunter, and T. Ruml.
1995.
Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria.
J. Virol.
69:1093-1098[Abstract].
|
| 21.
|
Lee, Y.-M., and X.-F. Yu.
1998.
Identification and characterization of virus assembly intermediate complexes in HIV-1-infected CD4+ T cells.
Virology
243:78-93[Medline].
|
| 22.
|
Li, H. M., and L. J. Chen.
1997.
A novel chloroplastic outer membrane-targeting signal that functions at both termini of passenger polypeptides.
J. Biol. Chem.
18:10968-10974.
|
| 23.
|
Lingappa, J. R.,
R. L. Hill,
M. L. Wong, and R. S. Hegde.
1997.
A multistep, ATP-dependent pathway for assembly of human immunodeficiency virus capsids in a cell-free system.
J. Cell Biol.
136:567-581[Abstract/Free Full Text].
|
| 24.
|
Muckel, E., and J. Soll.
1996.
A protein import receptor of chloroplasts is inserted into the outer envelope membrane by a novel pathway.
J. Biol. Chem.
271:23846-23852[Abstract/Free Full Text].
|
| 25.
|
Otera, H.,
K. Okumoto,
K. Tateishi,
Y. Ikoma,
E. Matsuda,
M. Nishimura,
T. Tsukamoto,
T. Osumi,
K. Ohashi,
O. Higuchi, and Y. Fujiki.
1998.
Peroxisome targeting signal type 1 (PTS1) receptor is involved in import of both PTS1 and PTS2: studies with PEX5-defective CHO cell mutants.
Mol. Cell. Biol.
18:388-399[Abstract/Free Full Text].
|
| 26.
|
Pain, D.,
H. Murakami, and G. Blobel.
1990.
Identification of a receptor for protein import into mitochondria.
Nature
347:444-449[Medline].
|
| 27.
|
Pollard, V. W.,
W. M. Michael,
B. Naldalny,
M. C. Slomi,
P. Wang, and G. Dreyfuss.
1996.
A novel receptor mediated nuclear protein import pathway.
Cell
88:985-994.
|
| 28.
|
Rein, A.,
M. R. McClure,
N. R. Rice,
R. B. Luftig, and D. I. Schultz.
1986.
Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus.
Proc. Natl. Acad. Sci. USA
83:7246-7250[Abstract/Free Full Text].
|
| 29.
|
Rein, A.,
J. Mirro,
J. G. Haynes,
S. M. Ernst, and K. Nagashima.
1994.
Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein.
J. Virol.
68:1773-1781[Abstract/Free Full Text].
|
| 30.
|
Rhee, S. S., and E. Hunter.
1991.
Amino acid substitutions within the matrix protein of type D retroviruses affect assembly, transport and membrane association of a capsid.
EMBO J.
10:535-546[Medline].
|
| 31.
|
Rhee, S. S., and E. Hunter.
1987.
Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids.
J. Virol.
61:1045-1053[Abstract/Free Full Text].
|
| 32.
|
Rhee, S. S., and E. Hunter.
1990.
A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus.
Cell
63:77-86[Medline].
|
| 33.
|
Rhee, S. S., and E. Hunter.
1990.
Structural role of the matrix protein of type D retroviruses in Gag polyprotein stability and capsid assembly.
J. Virol.
64:4383-4389[Abstract/Free Full Text].
|
| 34.
|
Sabatini, D. D.,
G. Kreibich,
T. Morimoto, and M. Adesnik.
1982.
Mechanism for the incorporation of proteins in membranes and organelles.
J. Cell Biol.
92:1-22[Free Full Text].
|
| 35.
|
Sakalian, M.,
S. D. Parker,
R. A. Weldon, Jr., and E. Hunter.
1996.
Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro.
J. Virol.
70:3706-3715[Abstract].
|
| 36.
|
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5436-5467.
|
| 37.
|
Sommerfelt, M. A.,
S. S. Rhee, and E. Hunter.
1992.
Importance of p12 protein in Mason-Pfizer monkey virus assembly and infectivity.
J. Virol.
66:7005-7011[Abstract/Free Full Text].
|
| 38.
|
Soneoka, Y.,
S. M. Kingsman, and A. J. Kingsman.
1997.
Mutagenesis analysis of the murine leukemia virus matrix protein: identification of regions important for membrane localization and intracellular transport.
J. Virol.
71:5549-5559[Abstract].
|
| 39.
|
van Zaane, D.,
M. J. Dekker-Michielsen, and H. P. J. Bloemers.
1976.
Virus-specific precursor polypeptides in cells infected with Rauscher leukemia virus: synthesis, identification, and processing.
Virology
75:113-129[Medline].
|
| 40.
|
Weldon, R. A., Jr.,
W. B. Parker,
M. Sakalian, and E. Hunter.
1998.
Type D retrovirus capsid assembly and release are active events requiring ATP.
J. Virol.
72:3098-3106[Abstract/Free Full Text].
|
| 41.
|
Yuan, X.,
X. Yu,
T. H. Lee, and M. Essex.
1993.
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor.
J. Virol.
67:6387-6394[Abstract/Free Full Text].
|
| 42.
|
Zhou, W.,
L. J. Parent,
J. W. Wills, and M. D. Resh.
1994.
Identification of a membrane binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids.
J. Virol.
68:2556-2569[Abstract/Free Full Text].
|
| 43.
|
Zollar, M. J., and M. Smith.
1984.
Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single stranded DNA template.
DNA
3:479-488[Medline].
|
Journal of Virology, July 1999, p. 5431-5437, Vol. 73, No. 7
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Vlach, J., Lipov, J., Rumlova, M., Veverka, V., Lang, J., Srb, P., Knejzlik, Z., Pichova, I., Hunter, E., Hrabal, R., Ruml, T.
(2008). D-retrovirus morphogenetic switch driven by the targeting signal accessibility to Tctex-1 of dynein. Proc. Natl. Acad. Sci. USA
105: 10565-10570
[Abstract]
[Full Text]
-
Life, R. B., Lee, E.-G., Eastman, S. W., Linial, M. L.
(2008). Mutations in the Amino Terminus of Foamy Virus Gag Disrupt Morphology and Infectivity but Do Not Target Assembly. J. Virol.
82: 6109-6119
[Abstract]
[Full Text]
-
Arnaud, F., Murcia, P. R., Palmarini, M.
(2007). Mechanisms of Late Restriction Induced by an Endogenous Retrovirus. J. Virol.
81: 11441-11451
[Abstract]
[Full Text]
-
Gill, M. B., Kutok, J. L., Fingeroth, J. D.
(2007). Epstein-Barr Virus Thymidine Kinase Is a Centrosomal Resident Precisely Localized to the Periphery of Centrioles. J. Virol.
81: 6523-6535
[Abstract]
[Full Text]
-
Mannigel, I., Stange, A., Zentgraf, H., Lindemann, D.
(2007). Correct Capsid Assembly Mediated by a Conserved YXXLGL Motif in Prototype Foamy Virus Gag Is Essential for Infectivity and Reverse Transcription of the Viral Genome. J. Virol.
81: 3317-3326
[Abstract]
[Full Text]
-
Murcia, P. R., Arnaud, F., Palmarini, M.
(2007). The Transdominant Endogenous Retrovirus enJS56A1 Associates with and Blocks Intracellular Trafficking of Jaagsiekte Sheep Retrovirus Gag. J. Virol.
81: 1762-1772
[Abstract]
[Full Text]
-
Bauerova-Zabranska, H., Stokrova, J., Strisovsky, K., Hunter, E., Ruml, T., Pichova, I.
(2005). The RNA Binding G-patch Domain in Retroviral Protease Is Important for Infectivity and D-type Morphogenesis of Mason-Pfizer Monkey Virus. J. Biol. Chem.
280: 42106-42112
[Abstract]
[Full Text]
-
Cartellieri, M., Herchenroder, O., Rudolph, W., Heinkelein, M., Lindemann, D., Zentgraf, H., Rethwilm, A.
(2005). N-Terminal Gag Domain Required for Foamy Virus Particle Assembly and Export. J. Virol.
79: 12464-12476
[Abstract]
[Full Text]
-
Stansell, E., Tytler, E., Walter, M. R., Hunter, E.
(2004). An Early Stage of Mason-Pfizer Monkey Virus Budding Is Regulated by the Hydrophobicity of the Gag Matrix Domain Core. J. Virol.
78: 5023-5031
[Abstract]
[Full Text]
-
Lecellier, C.-H., Neves, M., Giron, M.-L., Tobaly-Tapiero, J., Saib, A.
(2002). Further Characterization of Equine Foamy Virus Reveals Unusual Features among the Foamy Viruses. J. Virol.
76: 7220-7227
[Abstract]
[Full Text]
-
Wilk, T., Geiselhart, V., Frech, M., Fuller, S. D., Flugel, R. M., Lochelt, M.
(2001). Specific Interaction of a Novel Foamy Virus Env Leader Protein with the N-Terminal Gag Domain. J. Virol.
75: 7995-8007
[Abstract]
[Full Text]
-
Eastman, S. W., Linial, M. L.
(2001). Identification of a Conserved Residue of Foamy Virus Gag Required for Intracellular Capsid Assembly. J. Virol.
75: 6857-6864
[Abstract]
[Full Text]
-
Tobaly-Tapiero, J., Bittoun, P., Giron, M.-L., Neves, M., Koken, M., Saïb, A., de Thé, H.
(2001). Human Foamy Virus Capsid Formation Requires an Interaction Domain in the N Terminus of Gag. J. Virol.
75: 4367-4375
[Abstract]
[Full Text]
-
Rumlova-Klikova, M., Hunter, E., Nermut, M. V., Pichova, I., Ruml, T.
(2000). Analysis of Mason-Pfizer Monkey Virus Gag Domains Required for Capsid Assembly in Bacteria: Role of the N-Terminal Proline Residue of CA in Directing Particle Shape. J. Virol.
74: 8452-8459
[Abstract]
[Full Text]
-
Ono, A., Orenstein, J. M., Freed, E. O.
(2000). Role of the Gag Matrix Domain in Targeting Human Immunodeficiency Virus Type 1 Assembly. J. Virol.
74: 2855-2866
[Abstract]
[Full Text]
-
Parker, S. D., Hunter, E.
(2000). A Cell-Line-Specific Defect in the Intracellular Transport and Release of Assembled Retroviral Capsids. J. Virol.
74: 784-795
[Abstract]
[Full Text]
-
Sakalian, M., Hunter, E.
(1999). Separate Assembly and Transport Domains within the Gag Precursor of Mason-Pfizer Monkey Virus. J. Virol.
73: 8073-8082
[Abstract]
[Full Text]